Completed PHASE2 INTERVENTIONAL 1-arm NCT00841568

A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]

Sponsor: Otsuka Pharmaceutical Co., Ltd.

Conditions Autosomal Dominant Polycystic Kidney Disease

Interventions OPC-41061

Updated 7 times since 2017 Last updated: Aug 15, 2018 Started: Apr 30, 2006 Primary completion: Nov 30, 2010 Completion: Nov 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00841568, this PHASE2 trial focuses on Autosomal Dominant Polycystic Kidney Disease and remains completed. Sponsored by Otsuka Pharmaceutical Co., Ltd., it has been updated 7 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Oct 2018 — Jan 2021 [monthly]

Completed PHASE2
Aug 2018 — Oct 2018 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Aug 2018 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Otsuka Pharmaceutical Co., Ltd.

Data source: Otsuka Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kanto Region, Japan